Compare Sana Biotechnology Inc (SANA) vs Workiva Inc (WK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Workiva Inc — how do they compare? Sana Biotechnology Inc trades at $3.19 (market cap $947.48M), while Workiva Inc trades at $72.76 (market cap $3.96B). The key difference: Workiva Inc is far larger — about 4.2× Sana Biotechnology Inc's market cap, and Workiva Inc is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| SANA | WK | |
|---|---|---|
Market Cap | $947.48M | $3.96B |
Sector | Health | Technology |
52-Week High | $5.92 | $93.31 |
52-Week Low | $2.68 | $44.31 |
Enterprise Value | $860.73M | $3.94B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.45, down 10.39% today, reflecting bearish technical signals and negative profitability metrics. The company reported a net loss of $244.17 million for 2025, with ROE at -152.87%. Recent news includes investor conference presentations and a peer-reviewed publication in The New England Journal of Medicine highlighting clinical data for type 1 diabetes treatment.
Analyst consensus is strongly bullish with 81.82% buy ratings, but high cash burn and negative earnings pose significant risks. Upside potential hinges on clinical success and future profitability, while downside risks include sustained losses and competitive pressures in biotechnology.
Workiva (WK) trades at $73.71, down 3.71% today but showing strong fundamental momentum with three consecutive quarterly earnings beats. The stock maintains bullish technical positioning near key support at $72 with an overall bullish signal from moving averages. Recent Q2 2026 results showed 19% revenue growth to $255 million, exceeding guidance, while the company continues to expand its AI capabilities with new product launches.
The outlook remains positive with 89% analyst buy ratings and an $82.50 consensus target offering 12% upside. However, elevated valuation multiples (P/E 86.6) and negative 2025 net income present risks. Key catalysts include continued AI adoption and Q3 earnings, while competition and execution risks warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Workiva Inc
Workiva is a leading provider of cloud-based platforms for complex reporting and compliance. It enables organizations to connect and manage data across financial reporting, ESG (Environmental, Social, and Governance), and GRC (Governance, Risk, and Compliance), serving as a single source of truth for auditable, transparent disclosures to regulators and stakeholders.
Read more on WK →
